{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:34:15Z","timestamp":1789533255052,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016936","name":"Loxo Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016936","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical bleeding events are reported here from 773 patients with B\u2010cell malignancies receiving pirtobrutinib monotherapy from the phase 1\/2 BRUIN study (ClinicalTrials.gov identifier: NCT03740529), either in the presence or absence of antithrombotic therapy (antithrombotic exposed [AT\u2010E], <jats:italic>n<\/jats:italic>\u00a0=\u00a0216; antithrombotic nonexposed [AT\u2010NE], <jats:italic>n<\/jats:italic>\u00a0=\u00a0557). Among the AT\u2010E cohort, 51.9% received platelet aggregation inhibitors, 36.6% received direct factor Xa inhibitors, 18.5% received heparins, 5.6% received salicylic acid for indications other than platelet aggregation inhibition, and 2.3% received thrombolytics. Warfarin was not permitted. Any\u2010grade bleeding\/bruising events occurred in 97 patients (44.9%; 95% confidence interval [CI], 38.3\u201351.5) in the AT\u2010E cohort and 181 patients (32.5%; 95% CI, 28.6\u201336.4) in the AT\u2010NE cohort. Most bleeding\/bruising events in both cohorts began within the first 6 months of treatment (AT\u2010E: 65.4%; AT\u2010NE: 72.5%). Contusion was the most common bleeding\/bruising event in both cohorts (AT\u2010E: 22.7%; AT\u2010NE: 18.1%). Grade \u22653 bleeding\/bruising events were reported in six patients (2.8%) in the AT\u2010E cohort and 11 patients (2.0%) in the AT\u2010NE cohort. Bleeding\/bruising events requiring or prolonging hospitalization were reported in 2.3% and 1.6% of patients in the AT\u2010E and AT\u2010NE cohorts, respectively. No bleeding\/bruising events led to pirtobrutinib dose reduction or permanent discontinuation in the AT\u2010E cohort, and one patient (0.2%) in the AT\u2010NE cohort experienced an event requiring dose reduction. These data support the safety of pirtobrutinib in patients requiring antithrombotic therapies.<\/jats:p>","DOI":"10.1002\/jha2.1013","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T10:10:05Z","timestamp":1727431805000},"page":"929-939","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3331-9491","authenticated-orcid":false,"given":"Nicole","family":"Lamanna","sequence":"first","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center Columbia University  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"Alfred Health  Melbourne Victoria Australia"},{"name":"Central Clinical School Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"Division of Hematology The Ohio State University Comprehensive Cancer Center  Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro J.","family":"Alencar","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center University of Miami, Miller School of Medicine  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d  Bologna Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche Universit\u00e0 di Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"Tennessee Oncology and OneOncology  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Fakhri","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology University of California  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrin","family":"Kontos","sequence":"additional","affiliation":[{"name":"Loxo@Lilly  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Konig","sequence":"additional","affiliation":[{"name":"Loxo@Lilly  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Ruppert","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindya","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Loxo@Lilly  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sizelove","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Compte","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E.","family":"Tsai","sequence":"additional","affiliation":[{"name":"Loxo@Lilly  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Maria Sklodowska\u2010Curie National Research Institute of Oncology  Krakow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014162"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01485-x"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143648"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051103"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318259"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103238"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.287"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jscai.2023.100608"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(98)70471-3"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583294"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1142"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.126672"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028761"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S326627"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051504"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01252-y"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005621"},{"issue":"1","key":"e_1_2_12_22_1","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez EB","year":"2023","journal-title":"Blood"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"issue":"26","key":"e_1_2_12_24_1","first-page":"3137","article-title":"Pirtobrutinib: a new hope for patients with BTK inhibitor\u2010refractory lymphoproliferative disorders","volume":"141","author":"Thompson PA","year":"2023","journal-title":"Blood"},{"key":"e_1_2_12_25_1","unstructured":"U.S. Food and Drug Administration.FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma. 27 January 2023. Accessed 7 December 2023https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010pirtobrutinib\u2010relapsed\u2010or\u2010refractory\u2010mantle\u2010cell\u2010lymphoma"},{"key":"e_1_2_12_26_1","unstructured":"European Medicines Agency.Jaypirca \u2013 EPAR medicine overview.2023. Accessed 7 December 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jaypirca"},{"key":"e_1_2_12_27_1","unstructured":"The ASCO Post.FDA grants accelerated approval to pirtobrutnib for CLL\/SLL. 2023. Accessed 29 December 2023.https:\/\/ascopost.com\/news\/december\u20102023\/fda\u2010grants\u2010accelerated\u2010approval\u2010to\u2010pirtobrutinib\u2010for\u2010cllsll"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7513"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176350951"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18995"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281402"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.1013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T10:19:33Z","timestamp":1739355573000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.1013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1002\/jha2.1013"],"URL":"https:\/\/doi.org\/10.1002\/jha2.1013","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"2024-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}